Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DWTXNASDAQ:MDCXNASDAQ:RVPHNASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$4.80+0.4%$4.95$1.62▼$29.28$9.14M1.881.61 million shs10,290 shsMDCXMedicus Pharma$2.58+0.4%$4.28$1.80▼$8.94$34.88MN/A424,208 shs120,773 shsRVPHReviva Pharmaceuticals$0.67-6.4%$0.84$0.49▼$4.28$33.65M0.111.16 million shs790,360 shsSHPHShuttle Pharmaceuticals$3.60+4.3%$5.70$3.00▼$107.40$1.52M-1.175,212 shs128,753 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics+0.42%-0.41%-15.94%-29.72%+479,999,900.00%MDCXMedicus Pharma+0.39%-3.37%-66.84%-26.07%+257,999,900.00%RVPHReviva Pharmaceuticals-6.39%-15.00%-24.27%-38.73%-50.80%SHPHShuttle Pharmaceuticals+4.35%-35.54%-31.43%-64.50%+359,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDWTXDogwood Therapeutics1.3333 of 5 stars3.50.00.00.00.60.00.6MDCXMedicus Pharma1.8079 of 5 stars3.80.00.00.02.00.80.0RVPHReviva Pharmaceuticals2.2061 of 5 stars3.61.00.00.00.63.30.6SHPHShuttle Pharmaceuticals0.8337 of 5 stars0.04.00.00.01.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDWTXDogwood Therapeutics 3.00Buy$10.00108.33% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50810.85% UpsideRVPHReviva Pharmaceuticals 3.29Buy$9.001,235.31% UpsideSHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DWTX, MDCX, SHPH, and RVPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/3/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/20/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $3.005/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/24/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AMDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$4.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/A-217.12%-34.74%8/6/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%6/27/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)SHPHShuttle Pharmaceuticals-$9.15M-$4.15N/A∞N/AN/A-1,203.10%-370.42%N/ALatest DWTX, MDCX, SHPH, and RVPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RVPHReviva Pharmaceuticals-$0.21-$0.13+$0.08-$0.13N/AN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A5/8/2025Q1 2025SHPHShuttle PharmaceuticalsN/A-$7.50N/A-$0.30N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/A3/31/2025Q4 2024RVPHReviva Pharmaceuticals-$0.22-$0.15+$0.07-$0.15N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDWTXDogwood TherapeuticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDWTXDogwood TherapeuticsN/A7.437.43MDCXMedicus PharmaN/A1.531.53RVPHReviva PharmaceuticalsN/A0.540.54SHPHShuttle PharmaceuticalsN/A2.782.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDWTXDogwood Therapeutics9.05%MDCXMedicus PharmaN/ARVPHReviva Pharmaceuticals63.18%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipDWTXDogwood Therapeutics3.90%MDCXMedicus PharmaN/ARVPHReviva Pharmaceuticals27.18%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AMDCXMedicus PharmaN/A13.57 millionN/AN/ARVPHReviva Pharmaceuticals546.74 million34.04 millionOptionableSHPHShuttle Pharmaceuticals5440,000384,000Not OptionableDWTX, MDCX, SHPH, and RVPH HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Holdings Inc trading halted, news pendingJune 14, 2025 | msn.comShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13, 2025 | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12, 2025 | quiverquant.comShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12, 2025 | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deShuttle Pharma Provides Corporate UpdateMay 15, 2025 | globenewswire.comShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comShuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025April 24, 2025 | nasdaq.comShuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 21, 2025 | globenewswire.comShuttle Pharmaceuticals files provisional patent application with USPTOApril 12, 2025 | markets.businessinsider.comShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApril 10, 2025 | globenewswire.comShuttle Pharmaceuticals Appoints New Interim CEO and CSOMarch 31, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical TrialMarch 13, 2025 | quiverquant.comShuttle Pharma Announces Closing of $5.75 Million Underwritten OfferingMarch 13, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business ActivitiesMarch 12, 2025 | finanznachrichten.deShuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEOMarch 12, 2025 | markets.businessinsider.comShuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offeringMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDWTX, MDCX, SHPH, and RVPH Company DescriptionsDogwood Therapeutics NASDAQ:DWTX$4.80 +0.02 (+0.42%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$4.83 +0.03 (+0.63%) As of 06/18/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Medicus Pharma NASDAQ:MDCX$2.58 +0.01 (+0.39%) As of 06/18/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Reviva Pharmaceuticals NASDAQ:RVPH$0.67 -0.05 (-6.39%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.69 +0.02 (+2.82%) As of 06/18/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Shuttle Pharmaceuticals NASDAQ:SHPH$3.60 +0.15 (+4.35%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.52 -0.08 (-2.22%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
